IDH1 and central nervous system cancer: Notably, within IDH‐mt glioma cases, TERT promoter mutations were detected in all oligodendrogliomas but only in 4.55% of astrocytomas, consistent with the descriptions provided in the WHO CNS guidelines and supported by previous studies [25].